News
Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart
— First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hypertrophy and fibrosis
— Peer-reviewed publication in the Journal of the American College of Cardiology
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of the American College of Cardiology. The data confirm that the inhibition of the naturally occurring miR-132 microRNA via an antisense microRNA can prevent pathological cardiac remodeling in hypertrophic heart disease.
Company News: Aleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional Deep Brain Stimulation System
— First system implanted at University Hospital of Dresden / Prof. Sobottka
— Post-market clinical follow-up and revenue-generating study in the EU
— Targeting US FDA IDE approval in Q4, 2021
Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced the successful implantation of a first patient with the directSTIMTM Directional Deep Brain Stimulation System.
Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections
— IM-250 reduces viral load, viral shedding and recurrence rate
— Potential treatment for persistent, neurotrophic herpes simplex
Innovative Molecules GmbH, a drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced preclinical data demonstrating that the Company’s drug candidate IM-250 affects acute as well as chronic neural Herpes simplex virus (HSV) infections in mice and guinea pigs. IM-250 is a proprietary, novel helicase-primase inhibitor.
Company News: Innovative Molecules raises €20 million Series A equity financing round
— Proceeds dedicated to advance Herpes simplex treatment IM-250 to Phase II
— IM-250 demonstrates unprecedented impact on viral reservoir in preclinical studies
Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its €20 million Series A equity financing round led by LSP (Life Sciences Partners).